0
February 11, 1939, Vol 112, No. 6 >
Other Articles | February 11, 1939

SULFAPYRIDINE—THE NEW SULFANILAMIDE DERIVATIVE

JAMA. 1939;112(6):540-541. doi:10.1001/jama.1939.02800060056013.
Text Size: A A A
Published online
Article
References

For more than two years the drug sulfanilamide has attracted more interest than any other therapeutic agent, because of the spectacular results which followed its use in many conditions, including certain specific effects in infections with the beta strain of the hemolytic streptococcus. The extensive employment of the remedy has indicated not only the truly remarkable results of the drug but also its decided toxicity. Repeatedly The Journal and the Council on Pharmacy and Chemistry have warned against indiscriminate administration.

As always happens after a new discovery in the field of medicine, chemists everywhere, particularly in the employ of pharmaceutic houses, have been stimulated to attempt to find derivatives of sulfanilamide which might be still better than the parent compound. A host of such products has been announced in the chemical and pharmacologic literature. Most have been disappointing in results and frequently more toxic than sulfanilamide. Early in 1938 Whitby

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours

First Page Preview

View Large
First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

Letters

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Response

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs

More Listings at
JAMACareerCenter.com >

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems